Jakob Dupont is VP at OncoMed Pharmaceuticals Inc (OMED). They have made 8 open-market trades across 3 companies since 2014, most recently 2026-06-30.
CIK 0001553335
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PYXS | SELL · 10b5-1 | 2026-06-30 | 2026-07-02 | $3.06 | $107K | -4.7% | +19.0% | -9.2% |
| ATRA | SELL · 10b5-1 | 2023-03-02 | 2023-03-06 | $3.63 | $18K | -9.6% | -18.7% | -54.4% |
| ATRA | SELL · 10b5-1 | 2022-11-16 | 2022-11-18 | $4.49 | $19K | +4.3% | -19.0% | +2.8% |
| ATRA | SELL · 10b5-1 | 2022-08-16 | 2022-08-18 | $5.03 | $21K | -13.7% | -17.0% | -0.4% |
| ATRA | SELL · 10b5-1 | 2022-05-17 | 2022-05-19 | $5.32 | $21K | -6.2% | +25.4% | -8.3% |
| ATRA | SELL · 10b5-1 | 2022-03-01 | 2022-03-03 | $9.86 | $22K | -9.9% | +4.1% | -48.9% |
| ATRA | SELL | 2022-02-10 | 2022-02-14 | $16.00 | $80K | -8.2% | -35.7% | -63.1% |
| ATRA | SELL | 2022-01-03 | 2022-01-05 | $16.01 | $160K | -4.1% | -6.0% | -40.2% |
| ATRA | SELL | 2021-12-01 | 2021-12-03 | $17.94 | $90K | -5.7% | -0.6% | -44.6% |
| ATRA | SELL · 10b5-1 | 2021-11-16 | 2021-11-18 | $17.12 | $38K | -1.8% | -11.2% | -16.6% |
| ATRA | SELL | 2021-11-02 | 2021-11-04 | $16.41 | $82K | -10.7% | -12.7% | -24.2% |
| ATRA | SELL · 10b5-1 | 2021-08-17 | 2021-08-19 | $12.53 | $27K | +26.1% | +36.7% | +49.8% |
| ATRA | SELL | 2021-05-18 | 2021-05-20 | $14.55 | $151K | -4.5% | +8.1% | -13.6% |
| GOSS | SELL | 2019-12-27 | 2019-12-31 | $15.04 | $632K | -11.0% | -13.8% | -34.3% |
| OMED | SELL | 2016-01-11 | 2016-01-12 | $20.01 | $100K | -41.7% | -47.5% | -40.1% |
| OMED | SELL | 2016-01-06 | 2016-01-08 | $22.28 | $96K | -18.1% | -55.5% | -47.5% |
| OMED | SELL · 10b5-1 | 2015-12-10 | 2015-12-14 | $20.49 | $51K | -32.1% | -32.1% | -53.5% |
| OMED | SELL · 10b5-1 | 2015-11-10 | 2015-11-12 | $21.17 | $53K | -32.1% | -0.5% | -59.3% |
| OMED | SELL · 10b5-1 | 2015-10-26 | 2015-10-27 | $20.00 | $100K | -32.1% | -0.5% | -54.5% |
| OMED | SELL · 10b5-1 | 2015-08-10 | 2015-08-12 | $22.25 | $56K | -32.1% | -0.5% | -0.5% |
| OMED | SELL · 10b5-1 | 2015-07-10 | 2015-07-13 | $20.13 | $50K | -32.1% | -0.5% | -0.5% |
| OMED | SELL · 10b5-1 | 2015-07-06 | 2015-07-07 | $21.22 | $53K | -32.1% | -0.5% | -0.5% |
| OMED | SELL · 10b5-1 | 2015-04-10 | 2015-04-14 | $26.51 | $40K | -32.1% | -0.5% | -0.5% |
| OMED | SELL · 10b5-1 | 2015-03-10 | 2015-03-12 | $27.17 | $41K | -32.1% | -0.5% | -0.5% |
| OMED | SELL · 10b5-1 | 2015-02-10 | 2015-02-12 | $24.23 | $36K | -32.1% | -0.5% | -0.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.